Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Concizumab · Alhemo, MAB-2021

Monoclonal antibody · Antagonist of Tissue factor pathway inhibitor (TFPI) · developed by Novo Nordisk

Approved FDA, Dec 2024
NVO Developer
1 Registered trials

What is Concizumab?

Concizumab is a monoclonal antibody that binds and antagonizes endogenous tissue factor pathway inhibitor (TFPI), enhancing factor Xa production and thrombin generation during the initiation of coagulation. It is studied in congenital haemophilia. Its effect does not depend on FVIII or FIX inhibitory antibodies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Alhemo, MAB-2021, NN-7415
Drug type
Monoclonal antibody
Targets
Tissue factor pathway inhibitor (TFPI)
Mechanism
Antagonist of Tissue factor pathway inhibitor (TFPI)
Pathways
coagulation cascade, factor Xa production, thrombin generation
Therapy area
Hematology
Developer
Novo Nordisk Inc (NVO)
FDA status
Approved as Alhemo (December 20, 2024), BLA761315 · FDA label
UNII
68603V9EAF

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 1, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04921956 N/A Congenital Haemophilia No longer available NVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Congenital Haemophilia

Other drugs acting on TFPI

More from Novo Nordisk

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind Concizumab

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.